Publication | Open Access

Soluble E-selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor-inhibiting anti-neovascularization agent, evaluated in phase I clinical trial

Soluble E-selectinTumor-inhibiting Anti-neovascularization AgentMedicinePharmacologyPathologyTumor TargetingAnti-cancer AgentCancer PatientsCancer TreatmentOncologyTumor MicroenvironmentCancer Research